Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$44.85 USD

44.85
1,027,675

-0.08 (-0.18%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $44.86 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold

by Zacks Equity Research

QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons Growth Investors Will Love Qiagen (QGEN)

by Zacks Equity Research

Qiagen (QGEN) could produce exceptional returns because of its solid growth attributes.

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

PerkinElmer's (PKI) Arm Gets FDA EUA Nod for Latest Assay

by Zacks Equity Research

PerkinElmer's (PKI) unit receives FDA's EUA nod for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG) that could aid in future understanding and provide insights on immune responses to SARS-CoV-2.

Thermo Fisher (TMO) Boosts COVID Testing With Wastewater Kit

by Zacks Equity Research

Thermo Fisher's (TMO) wastewater surveillance method is set to identify asymptomatic carriers on college campuses to monitor regional spread among communities.

QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract

by Zacks Equity Research

QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.

QGEN or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

QGEN vs. ILMN: Which Stock Is the Better Value Option?

Trina Mukherjee headshot

3 Promising MedTech Stocks to Snap Up in Second-Half 2021

by Trina Mukherjee

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.

Riya Anand headshot

3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate

by Riya Anand

Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.

QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat

by Zacks Equity Research

QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.

QIAGEN's (QGEN) Kits Hit New Milestone for Sample Preparation

by Zacks Equity Research

QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.

QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 1.52% and 0.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance

by Zacks Equity Research

According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.

QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark

by Zacks Equity Research

QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.

QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt

by Zacks Equity Research

With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.

LabCorp (LH) Expands Testing Portfolio With the Launch of CDx

by Zacks Equity Research

LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.

QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal

by Zacks Equity Research

QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.

QIAGEN (QGEN) & Verogen Team Up to Employ NGS-Based Forensics

by Zacks Equity Research

QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.

Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status

by Zacks Equity Research

Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.